Антикоагулянтная терапия в лечении больного с фибрилляцией предсердий с позиций коморбидности: фокус на выбор

В статье рассмотрены вопросы выбора антикоагулянтной терапии у больных с фибрилляцией предсердий и рядом сопутствующих заболеваний – ишемической болезнью сердца, в том числе после чрескожных коронарных вмешательств, сахарным диабетом, хронической болезнью почек, хронической обструктивной болезнью легких, а также у лиц пожилого возраста. Приведены данные субанализов рандомизированного клинического исследования ARISTOTLE, свидетельствующие о высоком профиле эффективности и безопасности нового орального антикоагулянта апиксабана у данной категории больных.

1. Kraemer HC. Statistical issues in assessing comorbidity. Stat. Med., 1995, 14: 721-723.

2. Van den Akker M. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur. J. Gen. Pract. 1996, 2(2): 65-70.

3. Лазебник Л.Б. Старение и полиморбидность. Consilium Medicum, 2005, 12: 993-996

4. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care, 1993, 31(2): 141-154.

5. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/ Paisley study. Heart, 2001, 86: 516–521.

6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285: 2370–2375.

7. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 2006, 114: 119–125.

8. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J, 2006, 27: 949–953.

9. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol, 2009, 104: 1534–1539.

10. Lloyd‐Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framin gham Heart Study. Circulation, 2004, 110: 1042–1046.

11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-Ch, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W1, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K.J. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016, 37(38): 2893-2962.

12. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции. Клинические рекомендации: «Диагностика и лечение фибрилляции предсердий» 2017 года. webmed.irkutsk.ru/doc/pdf/af.pdf.

13. Рубаненко О.А. Коморбидная патология у пациентов с фибрилляцией предсердий. Известия Самарского научного центра Российской академии наук, 2015, 17(2): 367-370

14. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Prog ramme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2014 Mar, 16(3): 308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17.

15. Dorian P, Guerra PG, Kerr CR, O’Donnell SS, Crystal E, Gillis AM, Mitchell LB, Roy D, Skanes AC, Rose MS, Wyse DG. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol, 2009, 2: 218–224.

16. Cho JR, Angiolillo DJ. Percutaneous coronary intervention and atrial fibrillation: The triple therapy dilemma. J Thromb Thrombolysis, 2015, 39: 203–8. doi: 10.1007/s11239-014-1132-z.

17. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39(3): 213-260. doi: 10.1093/eurheartj/ehx419.

18. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, Aylward PE, Verheugt FW, Keltai M, Diaz R, Hanna M, Granger CB, Wallentin L. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol, 2013, 170: 215-220.

19. Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJ, Hanna M, Atar D, Cecilia Bahit M, Keltai M, Lopez-Sendon JL, Pais P, Ruzyllo W, Wallentin L, Granger CB, Alexander JH. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur. Heart J. Cardiovasc. Pharmacother., 2015, 1(2): 86–94.

20. Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am. J. Cardiovasc. Drugs, 2005, 5(5): 291–305.

21. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE, ATRIA Study Investigators.et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation, 2009, 119(10): 1363–1369.

22. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2011, 80(6): 572–586.

23. Hohnloser SH, Hijazi Z, Thomas L, Alexander J H, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J, 2012, 33(22): 2821–2830.

24. Soliman EZ, Prineas RJ, Go A S, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI, Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J, 2010, 159(6): 1102–1107.

25. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol, 2016 Jul 1, 1(4): 451-60. doi: 10.1001/jamacardio.2016.1170.

26. Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, Held C, Wallentin L, Granger CB, Palmer SM, Al-Khatib SM. Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. Int. J. Cardiol., 2016, 202: 589–594.

27. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest, 2010, 137(2): 263–272.

28. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur. Heart J, 2014, 35(28): 1864–1872.

29. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L, Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol, 2016, 1(6): 673–681.

30. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibril lation): Predictors, Characteristics, and Clinical Outcomes. J. Am. Coll. Cardiol., 2014, 63(20): 2141–2147.